Oncology

New overall survival analysis data on Yescarta from ZUMA-7 were presented at the ASCO 2023 meeting.

Among 19 patients with r/r B-ALL included in the analysis, all 19 achieved a CR or CRi.

Safety findings were also improved when compared with the previous CARTITUDE-1 study, suggesting the therapy may be better tolerated in earlier lines of therapy.

The study began enrollment in January 2023.

Additionally, promising efficacy signals were reported—namely response rates and disease control rates—in the phase 1 clinical trial (NCT04429087) data that were presented at the 2023 ASCO Annual Meeting.

Among 94 patients who were treated with obe-cel in the trial, 76% achieved a CR or CRi.

The autologous CAR T-cell therapy A2B530 is being investigated for solid tumors in the multicenter, first-in-human, phase 1/2 EVEREST-1 study.

Among 70 patients who were able to be evaluated for efficacy at 28 days or more, 91% achieved a complete response or a complete response with incomplete hematological recovery.

Follow-up data were presented from the discontinued phase 3 OVAL study.

There were no DLTs observed among the treated patients.

Maria Pia Morelli, MD, PhD, assistant professor at MD Anderson Cancer Center, discussed the first-in-human study of Sleeping Beauty TCR-T cells.

Among 49 patients who were included in the trial’s primary efficacy analysis set and received dose-level 2, the CR/CRi rate was 18.4%.

Review top news and interview highlights from the week ending June 2, 2023.

Genprex also announced preliminary data from the phase 1 portion of the trial evaluating Reqorsa, which is being presented at ASCO’s 2023 meeting.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The promising preclinical data, observed in an accurate model of brain metastases, support initiation of a phase 1 trial.

The BLA has a PDUFA action date of November 25, 2023.

The Type II variation application for ciltacabtagene autoleucel in adult patients with relapsed and lenalidomide-refractory multiple myeloma is supported by data from the phase 3 CARTITUDE-4 trial.

Alliance for Cancer Gene Therapy (ACGT) awarded The Edward Netter Leadership Award to Crystal Mackall, MD, of Stanford University.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The CEO, founder, and president of Siren Biotechnology discussed the preclinical data she presented at ASGCT’s 2023 meeting on the use of AAV immuno-gene therapy for high-grade gliomas.

The chief scientific officer at Candel Therapeutics discussed late-breaking data presented at ASGCT 2023.

Alliance for Cancer Gene Therapy (ACGT) recently hosted their 2023 Summit, a scientific gathering of cancer experts to discuss challenges and opportunities with cell and gene therapy.

The approval was based on data from the phase 1/2 EPCORE NHL-1 clinical trial.

The professor of internal medicine at UT Southwestern Medical Center shared his perspective on the current landscape of CAR-T cell therapy in the care of patients with myeloma.

Diane M. Simeone, MD, discussed the phase 1/2 EVEREST-1 trial, which seeks to assess the novel CAR T-cell therapy A2B530 in patients with solid tumors—hopefully progressing one-and-done engineered therapies in this population.

May is Brain Cancer Awareness Month, and the ACGT is raising awareness of the potential of the human immune system when combined with cell and gene therapy to defeat brain tumors.

The senior research fellow at Fred Hutch Cancer Center discussed findings from the PLAT-08 trial presented at ASGCT 2023.

Review top news and interview highlights from the week ending May 12, 2023.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.